| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
LONDON—In its recent Phase IIb DREAM study, GlaxoSmithKline'ssevere asthma drug mepolizumab—an injectable antibody treatment—reportedly reducedasthma attacks suffered by patients with a hard-to-treat form of the disease bynearly half. This has prompted GSK to profess to media sources and investorsthat is plans to move the new drug into final Phase III development before theend of 2012.
 
 
The DREAMstudy (not to be confused with the DREAM Project recently reported on by ddn) tested mepolizumab in patients with severe eosinophilicasthma—in this form of asthma, the patient's organs are damaged by a surplus ofwhite blood cells. The yearlong study involved 621 patients and indicated thatthe number of "clinically significant exacerbations" in patients mepolizumab thatwould normally require the used of oral corticosteroids or a hospital visit occurredat about half the rate of those patients taking placebo.
 
 
A major selling point of GSK's new monoclonal antibody-based drug, which targetsinterleukin-5, is that it is taken just once a month.
 
 
GSK may be hoping that the can offset some of thefinancial pain to come when the company loses patent protection for its asthmaand chronic obstructive pulmonary disease drug Seretide/Advair. This hope, andthe good study results, may explain why the drug is getting some attention bythe company now despite being in Phase II trials since the late 1990s—in partbecause such a small number of asthmatics suffer from this severe form of thedisease; reportedly, about 4 percent. 
 

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Clear sample tubes are shown in a clear tote with red lids in a sample prep robot with a blue and silver industrial lab background.

The crucial role of sample preparation in biotherapy manufacturing

Discover how better sample preparation can unlock improved assay accuracy and analytical results.
A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Three burgundy round and linear conformations of oligonucleotides are shown against a black background.

Accelerating RNA therapeutic testing with liver microphysiological platforms

Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue